Evidence map›Paper›PMID 38536523›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2024

Suitability of reduced dose glucocorticoids therapy regimen for antibody-associated vasculitis patients with TB: a retrospective study.

Rui Wen, Jingni Xiao, Ning Ding, Yong Zhong, Qiong Yuan, Jiali Li, Qi Wang, Hebin Xie, Jiao Qin

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 93% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Rui Wen *The Affiliated Changsha Central Hospital, Department of Nephrology, Hengyang Medical School, University of South China, Changsha, Hunan, 410004, China.
Jingni Xiao *The Affiliated Changsha Central Hospital, Department of Nephrology, Hengyang Medical School, University of South China, Changsha, Hunan, 410004, China.
Ning DingThe Affiliated Changsha Central Hospital, Department of Emergency, Hengyang Medical School, University of South China, Changsha, Hunan, 410004, China.
Yong ZhongDepartment of Nephrology, Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
Qiong YuanThe Affiliated Changsha Central Hospital, Department of Nephrology, Hengyang Medical School, University of South China, Changsha, Hunan, 410004, China.
Jiali LiThe Affiliated Changsha Central Hospital, Department of Nephrology, Hengyang Medical School, University of South China, Changsha, Hunan, 410004, China.
Qi WangThe Affiliated Changsha Central Hospital, Department of Nephrology, Hengyang Medical School, University of South China, Changsha, Hunan, 410004, China.
Hebin Xie *The Affiliated Changsha Central Hospital, Department of drug clinical trial institutions, Hengyang Medical School, University of South China, Changsha, Hunan, 410004, China.
Jiao Qin *The Affiliated Changsha Central Hospital, Department of Nephrology, Hengyang Medical School, University of South China, Changsha, Hunan, 410004, China. QinJ8429@163.com.
University of South China · CNCentral South University · CNChangsha Central Hospital · CN

Funding

Department of Science and Technology of Hunan Province Great No. kzd21074 and 2021SK53410Health Commission of Hunan Province Grant No. 202203052625Natural Science Foundation of Hunan Province Grant No. 2020JJ5611Natural Science Foundation of Hunan Province No. 2020JJ8044Scientific Research Foundation of Education Department of Anhui Province of China Grant No.22A0321
6 · The paper itself

Abstract

intentionImmunosuppressive therapy is the major treatment approach for patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). Due to impaired cellular immunological function and the use of glucocorticoids and immunosuppressants, AAV patients are predisposed to opportunistic infections, including tuberculosis (TB). This retrospective study aims to analyze the clinical characteristics of patients with AAV and TB and explore suitable glucocorticoid regimens for them. So as to provide a basis for future clinical guidelines and have important value for guiding clinical treatment.

methodsThis study retrospectively reviewed 58 AAV patients (18-80 years old) with TB admitted to Changsha Central Hospital Affiliated with the University of South China from 2016.1 to 2023.4 Patients were divided into standard-dose and reduced-dose glucocorticoid groups before retrospectively analyzing their medical records.

resultsA total of 58 AAV patients with TB were enrolled, with 15 dying throughout the monitoring period. Through analysis data, compared with the standard-dose group, the reduced group had less proteinuria and hematuria. In survival analysis, the reduced-dose glucocorticoid group had lower mortality than the standard-dose group (P = 0.03); however, no significant difference was noted in the use of immunoglobulin (P = 0.39), tuberculosis activity (P = 0.64), and age stratification (P = 0.40). The BVAS score before treatment and 6 months post-treatment suggest that the two regimens cause the same risk of ESKD (P > 0.05).

conclusionIn conclusion, the reduced glucocorticoid dose group can achieve the same curative effect as the standard dose group and has less damage to the kidney in hematuria and proteinuria. Therefore, the reduced glucocorticoid dose treatment regimen may be more suitable for AAV patients with TB.

Indexed as

Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisGlucocorticoidsTuberculosisAdolescentAdultAgedAged, 80 and overChinaFemaleHumansImmunosuppressive AgentsMaleMiddle AgedRetrospective StudiesYoung AdultGlucocorticoidsImmunosuppressive AgentsANCA-associated vasculitisEosinophilic granulomatous vasculitisGlucocorticoidsMyeloperoxidaseProteinase 3 granulomatous vasculitisTuberculosis

Identifiers

PMID38536523
OpenAlexW4393234059

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.